Joe Tippens Protocol

Fenbendazole gained broad public attention after Joe Tippens shared his personal cancer experience, which quickly spread across online health communities. What began as one man’s story has since become one of the most widely discussed alternative supplement protocols on the internet.

This article provides a comprehensive, structured overview of the Joe Tippens protocol — including its origins, the original regimen, later variations, maintenance schedules, the science behind fenbendazole, and important safety considerations. This content is for educational and documentation purposes only and does not constitute medical advice.

Who Is Joe Tippens?

In 2016, Joe Tippens was diagnosed with small cell lung cancer, one of the most aggressive forms of lung cancer. He began standard conventional therapy, including chemotherapy and radiation. During treatment, he reportedly experienced severe complications involving his esophagus, which made continuation extremely difficult.

Rather than stopping entirely, Joe shifted his attention toward recovery, resilience, and supportive routines. He became widely known online for openly sharing his choices and mindset during that period.

The Turning Point

In early 2017, Joe described hearing about an unconventional idea through a veterinary connection — that fenbendazole, an antiparasitic drug commonly used in veterinary medicine, had been discussed by some people as part of a broader supplement routine. He added fenbendazole to his regimen alongside several other supplements.

Over the following months, Joe reported significant changes in his scans. His story attracted widespread attention, and the routine he described — fenbendazole combined with vitamin E, curcumin, and CBD oil — became what is now commonly called the "Joe Tippens Protocol."

What Is Fenbendazole?

Fenbendazole is a benzimidazole antiparasitic originally developed for veterinary use. It is widely used to treat intestinal parasites in dogs, cats, and livestock. It is sold under brand names like Panacur and Safe-Guard and has been in use since the 1970s.

Although fenbendazole is not approved for human use by the FDA, its chemical cousin mebendazole (which shares the same mechanism of action) is an FDA-approved human antiparasitic. Both belong to the benzimidazole family and work by disrupting microtubule formation in cells.

For a detailed overview of fenbendazole’s veterinary applications and safety data, see: Fenbendazole’s Uses in Veterinary Medicine.

Why Researchers Are Interested in Fenbendazole for Cancer

Preclinical research has identified several mechanisms through which fenbendazole may affect cancer cells in laboratory settings:

• Microtubule disruption: Fenbendazole interferes with tubulin polymerization, which is essential for cell division. This is the same mechanism targeted by some established chemotherapy drugs like vincristine and paclitaxel.
• p53 pathway stabilization: A 2018 study published in Scientific Reports (Nature) found that fenbendazole stabilized the p53 tumor suppressor protein in human non-small cell lung cancer cells, leading to apoptosis (PMC6103891).
• Inhibition of glucose uptake: The same study showed fenbendazole reduced glucose uptake by cancer cells by downregulating GLUT transporters and hexokinase II, effectively starving tumor cells of their primary energy source.
• Proteasomal interference: Fenbendazole has shown activity against proteasome function, disrupting the protein recycling machinery that cancer cells depend on for rapid growth.

A 2020 review in Pharmacological Research further documented the anticancer potential of benzimidazole compounds, including fenbendazole, across multiple cancer cell lines (PMC7505114).

Important: These findings come from laboratory and animal studies. They do not constitute clinical proof of effectiveness in humans. No controlled clinical trials have yet validated fenbendazole as a cancer treatment.

Joe Tippens Protocol: Original Version

Below is the most commonly cited version of Joe Tippens’ original protocol, as widely shared across online communities. Dosages are presented as they are frequently quoted — they are not medical recommendations.

⭐ Original Protocol (Classic Version)

Supplement	Dosage	Schedule
Fenbendazole	222 mg	Daily for 3 consecutive days, then 4 days off. Repeat weekly.
Vitamin E	400–800 mg	Daily (tocotrienols preferred)
Curcumin	600 mg	Daily (two tablets with meals)
CBD Oil	25 mg	Daily

Notes:

• Fenbendazole is often suggested to be taken with a meal containing dietary fat to improve absorption.
• Granules reference: approximately 1 g of Panacur/Safe-Guard granules (commonly cited conversion).
• Liquid reference: if using a solution around 100 mg/mL, the commonly cited equivalent is 2.2 mL/day.

✅ Updated Protocol (Later Variation)

Over time, variations of the protocol emerged. The following is a commonly cited “updated” version that some online communities attribute to later discussions around Joe’s routine:

Component	Dosage	Notes
Fenbendazole	222 mg daily	Continuous daily use (no off days in some versions)
Onco Adjunct Pathway 1	2–4 mL, twice/day	Weight-dependent
Onco Adjunct Pathway 2	3 capsules, twice/day	Only when off chemotherapy
Onco Adjunct Pathway 3	1–2 capsules with meals	Part of a lower-sugar dietary strategy
Onco Adjunct Pathway 4	2 capsules, twice/day	Continuous

Maintenance Protocols

Some versions of the protocol are presented as long-term “maintenance” schedules for people who have completed an initial course. These frameworks are discussed extensively online but are not standardized medical guidelines.

Post-Remission Maintenance

Supplement	Dosage	Schedule
Fenbendazole	222 mg	3 times per week (with fat-containing meal), then 4 days off. Repeat.
Curcumin	600 mg	Daily, continuously (no pauses)
CBD Oil	25 mg	Daily, continuously

General Wellness Maintenance

Supplement	Dosage	Schedule
Fenbendazole	222 mg	3 times per week with fat-containing meal. 10 weeks on, 10 weeks off. Repeat cycle.
Curcumin	600 mg	Daily, continuously
CBD Oil	25 mg	Daily, continuously

---

Supplements Referenced in the Protocol

The key components of the Joe Tippens protocol — pharmaceutical-grade, with full lab documentation.

Disclaimer: For convenience only. Consult a licensed professional.

Fenbendazole Dosing: Safety Considerations

One of the most common questions surrounding the Joe Tippens protocol is about dosage safety. Since fenbendazole is not approved for human use, there are no established human dosing guidelines from regulatory agencies.

Key safety points to consider:

• Veterinary safety data: In animals, fenbendazole has a wide safety margin. Toxicity studies in dogs and rodents show that even doses 100x the therapeutic dose are tolerated without serious adverse effects.
• Liver function: Some users report monitoring liver enzymes during fenbendazole use, as benzimidazoles are metabolized by the liver. Periodic blood work is commonly recommended in online discussions.
• Drug interactions: Fenbendazole may interact with other medications, particularly those metabolized by CYP450 enzymes. Anyone taking prescription medications should consult their doctor.
• Quality and purity: Since fenbendazole products vary widely in formulation and purity, sourcing from a tested, transparent supplier is important.

For a detailed dosage breakdown and safety analysis, see: How Much Fenbendazole Is Too Much? A Safety-Focused Dosage Guide.

How Does Fenbendazole Compare to Ivermectin?

Both fenbendazole and ivermectin are antiparasitic drugs that have attracted attention for potential anticancer properties. While they share some overlapping mechanisms (microtubule disruption, immune modulation), they work through different primary pathways:

• Fenbendazole primarily targets tubulin and glucose metabolism in cancer cells.
• Ivermectin primarily affects PAK1 signaling, WNT-TCF pathways, and may promote immunogenic cell death.

Some protocols, including the ISOM Protocol, combine both compounds as part of a broader metabolic strategy. For a detailed comparison, see: Fenbendazole vs. Ivermectin: Safety, Strength, and Effectiveness.

Clinical Evidence and Limitations

It is critical to state clearly: there are no completed, peer-reviewed clinical trials that have validated the Joe Tippens protocol or fenbendazole as a cancer treatment in humans. The evidence base consists of:

• Preclinical studies (cell lines and animal models) showing anti-tumor activity
• Anecdotal reports and personal testimonials shared online
• Mechanistic plausibility based on fenbendazole’s known biological activity

Meanwhile, related research is progressing. A Phase I/II clinical trial (NCT05318469) at Cedars-Sinai is evaluating ivermectin combined with immunotherapy in metastatic breast cancer — an indication that the scientific community is taking antiparasitic drug repurposing seriously.

Real-world customer experiences with fenbendazole and ivermectin can be found on our Customer Notes & Experiences page. These are personal accounts, not clinical evidence.

Key Takeaways

• The Joe Tippens protocol originated from one man’s personal experience with fenbendazole during cancer treatment in 2016–2017.
• The original protocol combines fenbendazole (222 mg, 3 days on / 4 days off) with vitamin E, curcumin, and CBD oil.
• Later variations include continuous daily dosing and additional adjunct supplements.
• Preclinical research supports fenbendazole’s anti-tumor mechanisms (microtubule disruption, p53 stabilization, glucose uptake inhibition), but no clinical trials have validated it for cancer in humans.
• Fenbendazole is not FDA-approved for human use. Quality, purity, and dosing accuracy vary by source.
• Medical supervision is essential. Do not self-treat cancer with fenbendazole without professional guidance.

Disclaimer: This page is for informational and educational purposes only. It does not provide medical advice and does not recommend any treatment. Always consult a licensed healthcare provider before using any supplements, compounds, or protocols described here.

---

Scientific References

1. Dogra N, Kumar A, Mukhopadhyay T. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports (Nature), 8, 11926. PMC6103891
2. Tang M, et al. (2020). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. PMC7505114
3. Son DS, et al. (2020). The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immune Network, 20(4), e29. PMC7458798
4. Florio R, et al. (2019). Fenbendazole’s effect on human cancer cells in vitro and its pharmacological relevance. Journal of Biochemical and Molecular Toxicology, 33(6), e22315. PubMed 30887614

---

Protocol Stack (Quick Links)

Below are commonly referenced items from the Joe Tippens protocol. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.